Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD

Bone Marrow Transplantation

Volumn 43, Issue 10, 2009, Pages 779-785

  Novitzky, N ^a   Thomas, V ^a   du Toit, C ^a   McDonald, A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DECAY ACCELERATING FACTOR; FLUDARABINE; GANCICLOVIR; HLA ANTIGEN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 3; MESNA; PARACETAMOL; PETHIDINE; PROMETHAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ANTIBODY TITER; APHERESIS; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW BIOPSY; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENGRAFTMENT; EVENT FREE SURVIVAL; EX VIVO STUDY; FEMALE; FEVER; FUNGEMIA; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFILTRATE; LYMPH NODE IRRADIATION; MALE; NAUSEA; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; SEPSIS; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; T CELL DEPLETION; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYTARABINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SIBLINGS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 67349158688     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.390     Document Type: Article

References (37)

1. Anasetti C, Doney KC, Storb R, Meyers JD, Farewell VT, Buckner CD et al. Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty 'untransfused' patients. Ann Intern Med 1986; 104: 461-466.
2. Georges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol 2002; 75: 141-146.
3. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
4. Kumar R, Prem S, Mahapatra M, Seth T, Chowdhary DR, Mishra P et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant 2006; 37: 745-749.
5. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
6. Kroger N, Zabelina T, Renges H, Kroger W, Kordes U, Rischewski J et al. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Ann Hematol 2002; 81: 627-631.
7. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, et al., on behalf of GITMO/EBMT. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
8. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P et al. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graftversus-host disease. Blood 1986; 68 119-125.
9. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490-2497.
10. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; ii: 483-486.
11. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69-76.
12. Novitzky N, Thomas V, Hale G, Waldmann H. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. Bone Marrow Transplant 2005; 36: 675-682.
13. Novitzky N, Thomas V, Stubbings H, Hale G, Waldmann H. Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy 2004; 6: 450-456.
14. Srinivasan R, Espinoza-Delgado Y, Dorrance C, Igarashi T, Lundqvist A, Barrett J et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006; 133: 305-314.
15. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
16. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 2003; 17: 94-100; discussion 103-107.
17. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
18. Kang HJ, Shin HY, Choi HS, Ahn HS. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 2004; 34: 939-943.
19. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947-950.
20. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504-514.
21. Esmer C, Sánchez S, Ramos S, Molina B, Frias S, Carnevale A. DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am J Med Genet Part A 2004; 124A: 35-39.
22. Bird A Western Province Blood Transfusion Service, Cape Town, unpublished personal communication.
23. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J. Hematother 1996; 5: 213-226.
24. Hale G, Xia M-Q, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (Cdw 52). Tissue Antigens 1990; 35: 118-127.
25. Barrios M, Jiménez-Velasco A, Román-Gómez J, Madrigal ME, Castillejo JA, Torres A et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003; 88: 801-810.
26. Tzeng CH, Chen PM, Fan S, Liu JH, Chiou TJ, Hsieh R K. CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLAhaploidentical family donors. Bone Marrow Transplant 1996; 18: 273-277.
27. Schrezenmeier H, Passweg JR, Marsh JCW, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
28. Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schönberger S et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007; 13: 1338-1345.
29. Elfenbein GJ. Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized peripheral blood stem cells are equivalent for engraftment: Which to choose? Pediatr Transplant 2005; 9 (Suppl 7): 37-47.
30. Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG et al. CAMPATH-1 antibodies in stem cell transplantation. Cytotherapy 2001; 3: 145-164.
31. Novitzky N, Thomas V, du Toit C, Mcdonald A. In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved. Biol Blood Marrow Transplant 2008; 14: 709-718.
32. Gupta V, Ball SE, Sage D, Ortin M, Freires M, Gordon-Smith EC et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467-471.
33. Gupta V, Ball SE, Yi Ql, Sage D, McCann SR, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10: 867-876.
34. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357.
35. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404.
36. Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002; 74 1551-1559.
37. Mori T, Aisa Y, Shimizu T, Nakazato T, Yamazaki R, Ikeda Y et al. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor. Int J Hematol 2006; 83: 266-267.